- Home
- JAZZ vs WTRG Comparison
JAZZ vs WTRG Comparison
Compare JAZZ & WTRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAZZ | WTRG |
|---|---|---|
| Founded | 2003 | 1901 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Water Supply |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.2B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | JAZZ | WTRG |
|---|---|---|
| Price | $169.65 | $38.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | ★ $194.40 | $44.33 |
| AVG Volume (30 Days) | 1.6M | ★ 2.1M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 3.61% |
| EPS Growth | N/A | ★ 20.57 |
| EPS | N/A | ★ 2.40 |
| Revenue | ★ $4,157,832,999.00 | $2,379,887,000.00 |
| Revenue This Year | $6.00 | $13.46 |
| Revenue Next Year | $6.84 | $5.41 |
| P/E Ratio | ★ N/A | $15.84 |
| Revenue Growth | 4.14 | ★ 21.35 |
| 52 Week Low | $95.49 | $33.18 |
| 52 Week High | $182.99 | $42.37 |
Technical Indicators
Market Signals| Indicator | JAZZ | WTRG |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 39.63 |
| Support Level | $164.44 | $38.71 |
| Resistance Level | $182.75 | $40.00 |
| Average True Range (ATR) | 5.88 | 0.91 |
| MACD | -1.21 | -0.14 |
| Stochastic Oscillator | 34.58 | 10.97 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About WTRG Essential Utilities Inc.
Essential Utilities is a Pennsylvania-based holding company for US water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Its largest service territory is in Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. It completed the sale of its West Virginia gas utility and the bulk of its nonregulated assets in 2024. Essential shareholders would own a 31% stake in American Water Works if the proposed all-stock merger closes in 2027.